Kilitch Drugs (India) Ltd. Share Price

Kilitch Drugs Q1 FY26: Stable Revenue, Margin Pressure, Export Focus

As the earnings season is underway, several companies are declaring their results for the fourth quarter of the financial year 2025-26. Similarly, ITC Limited is also all set to announce its Q4 FY26 earnings soon. Along with the quarterly results, the FMCG giant might also declare a dividend for its shareholders. The company informed this through an exchange filing on May 7, 2026.

Kilitch Drugs Posts Stellar Q1 FY26 Performance with Massive Profit Surge.

Kilitch Drugs delivered an exceptional set of numbers for the June 2025 quarter, with strong revenue growth and an extraordinary jump in profitability. Sales grew 29% YoY to ₹43.1 crore from ₹33.4 crore in June 2024. EBIDT almost doubled, up 96% to ₹3.26 crore from ₹1.66 crore, reflecting improved operating efficiency. Net profit skyrocketed 1964% YoY to ₹2.27 crore from just ₹0.11 crore last year, while EPS jumped 125% to ₹1.73 from ₹0.77. Kilitch is setting up a greenfield facility at Khopoli, aimed at in-house production of injectables, eye-drops, oral solid dosage forms, and nutraceuticals. This move is expected to reduce outsourcing costs, broaden product range, and improve margins over time. At a market price of ₹434 and market cap of ₹759 crore, the stock trades at a PE of 28.4, supported by its sharp earnings improvement. Key takeaway: The company has delivered a turnaround quarter, with robust sales growth and exponential profit expansion, indicating strong operational momentum heading into FY26.

Kilitch Drugs Targets ₹1,000 Cr Revenue with New Khopoli Plant & Global Expansion

Mumbai-based pharma company Kilitch Drugs (India) Ltd. is aiming for a big leap—from its current ₹180 crore revenue to ₹1,000 crore over the next 3–4 years. This growth will be powered by a new plant, expansion into regulated markets, and a strong foothold in Africa. Growth Engine: Khopoli Facility • Investment: ₹125 crore in a 15-acre greenfield plant at Khopoli, Maharashtra • Timeline: Operations to begin by Q3FY25 • Capabilities: Will produce nutraceuticals, injectables, eye drops, and oral solid dosage forms • Global Standards: EU & USFDA compliant—key to entering regulated markets by FY28–29 • Goal: Bring in-house 60% of outsourced production → cost savings + margin boost Financial Impact: • FY25 Profit Target: ₹31 crore • Current EBITDA Margin: 17% (expected to improve post-expansion) • FY26: Transition year (slightly subdued) • FY27 Onwards: Higher margins, new products, and full capacity utilisation • Revenue Growth Target: 70–75% during ramp-up phase Africa: Kilitch’s Power Market • Operates in 38 African countries • Strong front-end setup; local manufacturing edge • Top 3 Brand in West Africa with paracetamol effervescent tablets (Roipar) • Ethiopia plant: Largest injectable cephalosporin unit in East Africa • Won a government tender—boost to FY26 revenue Stock Market View: • Clear Long-Term Vision: Five-fold revenue ambition with timelines and execution plan • Capex-Fuelled Margin Expansion: Lower dependency on outsourcing improves profitability • Global Market Access: US & EU compliance opens doors to higher-value markets • Africa Dominance: Sustained growth from a market many peers exited With steady execution, Kilitch Drugs could see re-rating potential in the stock, especially from FY27 when operating leverage, exports, and product mix start to reflect in financials.

Results

Abb India, Ajmera Realty & Infra India, Alicon Castalloy, Amines & Plasticizers, Alembic Pharmaceuticals, Artemis Medicare Services, Astral, Astrazeneca Pharma, Avalon Technologies, Antony Waste Handling Cell, Azad Engineering, Bajel Projects, Bayer Cropscience, Bombay Burmah Trading Corp, Bharat Forge, Biocon, Birla Corporation, Balmer Lawrie Investments, Bharat Parenterals, Carysil, Chemfab Alkalis, Cheviot Co, Cochin Shipyard, Concor, Cosmo First, Digispice Technologies, Dreamfolks Services, Eicher Motors, Essar Shipping, Filatex India, Galaxy Surfactants, Garware Technical Fibres, Gateway Distriparks, Gretex Corporate Services, Geecee Ventures, Greaves Cotton, Garden Reach Shipbuilders & Engineers, Garware Hi-Tech Films, Gujarat State Petronet, Gujarat Alkalies & Chemicals, Hbl Power Systems, Healthcare Global Enterprises, Hcl Infosystems, Ifci, Igarashi Motors India, Indian Hume Pipe Co, India Shelter Finance Corporation, Indo Amines, Inspirisys Solutions, Ircon International, Iris Business Services, ***** & Pharma, Khadim India, Kilitch Drugs (India), Kilburn Engineering, Kopran, Life Insurance Corp, Lincoln Pharma, Lumax Industries, Mayur Uniquoters, Global Health, Minda Corporation, Mindteck (India), Media Matrix Worldwide, Moneyboxx Finance, Mps, Mrf, Munjal Auto Industries, Nava, Ndr Auto Components, The New India Assurance Co, Nikhil Adhesives, Nocil, Oil India, Orient Paper & Industries, Page Industries, Pcbl, Peninsula Land, Prevest Denpro, RK Swamy, Rvnl, Sail, Sandhar Technologies, Sansera Engineering, Shalimar Paints, Shankara Building Products, Shilpa Medicare, Shreyas Shipping & Logistics, Snowman Logistics, Sobha, State Trading Corporation Of India, Steelcast, Sutlej Textiles & Industries, Tcc Concept, Tega Industries, Timken India, Transpek Industry, Tvs Holdings, Uni Abex Alloy Products, Unichem Laboratories, Uniparts India, Va Tech Wabag.

Kilitch Drugs (India) Ltd : Pharmaceutical Formulations

- Core Business: Engaged in manufacturing and marketing pharmaceutical formulations in various dosage forms. - Global Presence: Strong market presence in Africa, Asia, CIS, and Latin America. Business Expansion and Operations - New Project: Setting up a Green Field Pharmaceutical Project in Khopoli, Maharashtra, India. - Product Range: Producing Oral Tablets, Liquid Injectable Vials, Ophthalmic Drops, and Nasal Drops. - Operational Highlights: - Launched Cephalosporin facility in Ethiopia, boosting private market growth. - Secured a USD 9.13 million government supply tender in Ethiopia. - Increased capacity for Ophthalmic products at Mumbai plant. - High customer retention with clients like Intas, Mankind, and Indoco Remedies. Ethiopia Market Expansion - Ethiopian Operations: - Received significant USD 9.13 million government order, holding 70% market share. - INR 50 crores invested in facility with income tax benefits and local manufacturing advantages. Financial Targets and Outlook - Financial Strategy: - Utilizing INR 30 crores as working capital, targeting EBITDA positivity with government tender. - Anticipates 25%-30% year-on-year growth in FY '25, focusing on new product development. Learning Outcome: Understanding this pharmaceutical company's expansive operations, strategic initiatives in global markets, financial targets, and operational updates highlights the complexities and opportunities in the pharmaceutical industry, emphasizing growth through new projects, market expansions, and financial strategies.